A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT06703606

Status	RECRUITING
Phase	Phase 1
Sponsor	Pfizer
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (3)

- Male and 12 to \<75 years of age with a minimum body weight of 35 kg at the time of signing the informed consent.
- Diagnosis of severe hemophilia A (FVIII activity \<1%) without inhibitors.
- On emicizumab therapy at a standard clinical dose for e6 months.

Exclusion (12)

- Previous or current treatment for or history of coronary artery diseases, venous or arterial thrombosis, or ischemic disease.
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Known hemostatic defect other than hemophilia A.
- Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
- Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.

... and 7 more (see full listing online)

Locations (4 total)

Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
K J Somaiya Hospital & Research Centre, Mumbai, Maharashtra, India
... and 1 more locations